Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy
Open Access
- 22 March 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Stem Cell Research & Therapy
- Vol. 12 (1), 1-21
- https://doi.org/10.1186/s13287-021-02251-7
Abstract
In recent decades, a new method of cellular immunotherapy was introduced based on engineering and empowering the immune effector cells. In this type of immunotherapy, the immune effector cells are equipped with chimeric antigen receptor (CAR) to specifically target cancer cells. In much of the trials and experiments, CAR-modified T cell immunotherapy has achieved very promising therapeutic results in the treatment of some types of cancers and infectious diseases. However, there are also some considerable drawbacks in the clinical application of CAR-T cells although much effort is in progress to rectify the issues. In some conditions, CAR-T cells initiate over-activated and strong immune responses, therefore, causing unexpected side-effects such as systemic cytokine toxicity (i.e., cytokine release syndrome), neurotoxicity, on-target, off-tumor toxicity, and graft-versus-host disease (GvHD). To overcome these limitations in CAR-T cell immunotherapy, NK cells as an alternative source of immune effector cells have been utilized for CAR-engineering. Natural killer cells are key players of the innate immune system that can destroy virus-infected cells, tumor cells, or other aberrant cells with their efficient recognizing capability. Compared to T cells, CAR-transduced NK cells (CAR-NK) have several advantages, such as safety in clinical use, non-MHC-restricted recognition of tumor cells, and renewable and easy cell sources for their preparation. In this review, we will discuss the recent preclinical and clinical studies, different sources of NK cells, transduction methods, possible limitations and challenges, and clinical considerations.Keywords
This publication has 195 references indexed in Scilit:
- Inhibition of Intracellular Antiviral Defense Mechanisms Augments Lentiviral Transduction of Human Natural Killer Cells: Implications for Gene TherapyHuman Gene Therapy, 2012
- Revisiting human natural killer cell subset function revealed cytolytic CD56 dim CD16 + NK cells as rapid producers of abundant IFN-γ on activationProceedings of the National Academy of Sciences of the United States of America, 2010
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cellsLeukemia Research, 2009
- Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral methodCancer Gene Therapy, 2009
- CD56bright natural killer (NK) cells: an important NK cell subsetImmunology, 2009
- Engineering antigen-specific primary human NK cells against HER-2 positive carcinomasProceedings of the National Academy of Sciences of the United States of America, 2008
- Formation and function of the lytic NK-cell immunological synapseNature Reviews Immunology, 2008
- What is trogocytosis and what is its purpose?Nature Immunology, 2003
- Progress and problems with the use of viral vectors for gene therapyNature Reviews Genetics, 2003